Peer-reviewed veterinary case report
Canine lymphoma treated with CHOP-MA chemo shows 622-day survival
By Daters, A T et al.·Published in Veterinary and comparative oncology·2010·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
- Species:
- dog
Plain-English summary
A group of 65 dogs with multicentric lymphoma (a type of cancer affecting the lymph nodes) was treated with a combination of chemotherapy drugs, including mitoxantrone, to see how well it worked. On average, these dogs went into remission for about 302 days and lived for around 622 days after starting treatment. The study found that dogs in better health before treatment (substage a) had a longer survival time compared to those in worse health (substage b). This suggests that using mitoxantrone alongside other chemotherapy drugs may help improve outcomes for dogs with this condition.
People also search for: dog lymphoma treatment · mitoxantrone for dogs · canine cancer survival rates
Abstract
The purpose of this study was to evaluate the efficacy of adding mitoxantrone to a cyclophosphamide, doxorubicin, vincristine, L-asparaginase and prednisone containing protocol. Sixty-five dogs with multicentric lymphoma were evaluated for overall remission and survival times. Remission and survival time versus stage, substage, pretreatment hypercalcaemia and pretreatment steroid administration were also evaluated. Overall median remission for dogs with multicentric lymphoma was 302 days and overall median survival was 622 days. Of the dogs with multicentric lymphoma, 23 (35%) received all scheduled mitoxantrone doses. Only median survival versus substage was found to be significant (substage a median survival was 679 days and substage b median survival was 302 days, P = 0.025). Increasing the total combined dose of doxorubicin and mitoxantrone may improve remission times when compared with historical controls, and further studies are needed to determine how best to utilize mitoxantrone in multidrug chemotherapy protocols for canine multicentric lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20230577/